Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

• Status: Completed
• Trial end date: 2017-03-10
• Target enrollment: 0
• Participant gender: All

Summary

This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on Progression of Coronary Intermediate Lesion.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Li Bo
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Patients > 18, < 80 years old, with type 2 diabetes mellitus and angiographically proven Coronary Intermediate Lesion.

Exclusion Criteria:

• Allergy or hypersensitivity to any of the drug's components.

• Severe liver failure, moderate or severe kidney failure

• Malignant disease.

• Active infectious disease.

• Pregnancy or breastfeeding.